Introducing LEQEMBI IQLIK, the initial anti-amyloid therapy providing an option for patients and caregivers to administer injections from the comfort of their homes. Following a recommended treatment duration of 18 months, LEQEMBI IQLIK is set for release on October 6th, 2025, solely in the United States. This groundbreaking treatment aims to support individuals managing this persistent and advancing disease beyond the first phase of care.